Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 10 | 2021 | 4638 | 1.100 |
Why?
|
| Uterine Cervical Dysplasia | 5 | 2012 | 219 | 0.830 |
Why?
|
| Cancer Survivors | 3 | 2022 | 650 | 0.750 |
Why?
|
| Survivors | 7 | 2021 | 1031 | 0.730 |
Why?
|
| Deglutition | 3 | 2018 | 171 | 0.680 |
Why?
|
| Colposcopy | 6 | 2012 | 78 | 0.560 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2012 | 1833 | 0.550 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2016 | 1105 | 0.550 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2017 | 519 | 0.540 |
Why?
|
| Exercise Therapy | 3 | 2013 | 288 | 0.530 |
Why?
|
| Endpoint Determination | 1 | 2016 | 176 | 0.520 |
Why?
|
| Depression | 4 | 2020 | 1715 | 0.510 |
Why?
|
| Spectrum Analysis | 3 | 2012 | 139 | 0.510 |
Why?
|
| Depressive Disorder | 2 | 2017 | 557 | 0.510 |
Why?
|
| Deglutition Disorders | 2 | 2022 | 447 | 0.500 |
Why?
|
| Testicular Neoplasms | 2 | 2010 | 529 | 0.500 |
Why?
|
| Medication Adherence | 1 | 2019 | 492 | 0.480 |
Why?
|
| Health Behavior | 2 | 2010 | 603 | 0.480 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 840 | 0.470 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 901 | 0.470 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2010 | 1209 | 0.380 |
Why?
|
| Life Style | 3 | 2017 | 612 | 0.360 |
Why?
|
| Patient Compliance | 1 | 2013 | 667 | 0.340 |
Why?
|
| Attitude to Death | 1 | 2009 | 100 | 0.330 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 2594 | 0.310 |
Why?
|
| Biomedical Technology | 1 | 2007 | 35 | 0.300 |
Why?
|
| Motivation | 2 | 2009 | 499 | 0.290 |
Why?
|
| Papanicolaou Test | 3 | 2007 | 141 | 0.260 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 918 | 0.260 |
Why?
|
| Vaginal Smears | 3 | 2007 | 192 | 0.260 |
Why?
|
| Spectrometry, Fluorescence | 4 | 2012 | 209 | 0.260 |
Why?
|
| Patient Health Questionnaire | 2 | 2020 | 21 | 0.230 |
Why?
|
| Depressive Disorder, Major | 2 | 2020 | 441 | 0.220 |
Why?
|
| Female | 28 | 2021 | 141928 | 0.220 |
Why?
|
| Breast Neoplasms | 5 | 2021 | 15694 | 0.220 |
Why?
|
| Anxiety | 1 | 2009 | 1179 | 0.210 |
Why?
|
| Patient Satisfaction | 4 | 2012 | 915 | 0.210 |
Why?
|
| Mass Screening | 4 | 2020 | 1509 | 0.210 |
Why?
|
| Middle Aged | 20 | 2020 | 86204 | 0.200 |
Why?
|
| Adult | 19 | 2020 | 77950 | 0.190 |
Why?
|
| Stress, Psychological | 2 | 2004 | 1000 | 0.180 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 2195 | 0.180 |
Why?
|
| Quality of Life | 6 | 2021 | 4532 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 5437 | 0.180 |
Why?
|
| Humans | 33 | 2022 | 261506 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 3890 | 0.170 |
Why?
|
| Qualitative Research | 1 | 2021 | 556 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 3 | 2022 | 3976 | 0.170 |
Why?
|
| Aged | 15 | 2020 | 70117 | 0.160 |
Why?
|
| Surveys and Questionnaires | 6 | 2019 | 5687 | 0.160 |
Why?
|
| Graphite | 1 | 2018 | 15 | 0.160 |
Why?
|
| Comorbidity | 2 | 2016 | 2352 | 0.160 |
Why?
|
| Cross-Sectional Studies | 5 | 2017 | 4314 | 0.160 |
Why?
|
| Health Care Surveys | 1 | 2019 | 430 | 0.150 |
Why?
|
| Electromyography | 1 | 2018 | 226 | 0.150 |
Why?
|
| Adaptation, Psychological | 1 | 2021 | 764 | 0.150 |
Why?
|
| Aged, 80 and over | 8 | 2019 | 29902 | 0.140 |
Why?
|
| Interviews as Topic | 2 | 2020 | 497 | 0.140 |
Why?
|
| Metal Nanoparticles | 1 | 2018 | 164 | 0.140 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2016 | 56 | 0.140 |
Why?
|
| Sertraline | 1 | 2016 | 45 | 0.140 |
Why?
|
| Risk Factors | 5 | 2016 | 17523 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2019 | 1544 | 0.130 |
Why?
|
| Monitoring, Physiologic | 1 | 2018 | 502 | 0.130 |
Why?
|
| Serotonin | 1 | 2016 | 264 | 0.130 |
Why?
|
| Remote Sensing Technology | 1 | 2013 | 12 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 799 | 0.120 |
Why?
|
| Smoking | 2 | 2016 | 2440 | 0.120 |
Why?
|
| Time Factors | 4 | 2019 | 12926 | 0.120 |
Why?
|
| Neoplasm Staging | 4 | 2019 | 13658 | 0.120 |
Why?
|
| Dehydration | 1 | 2013 | 87 | 0.110 |
Why?
|
| Computers, Handheld | 1 | 2013 | 69 | 0.110 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2013 | 133 | 0.110 |
Why?
|
| Alphapapillomavirus | 2 | 2012 | 171 | 0.110 |
Why?
|
| Papillomaviridae | 1 | 2016 | 624 | 0.110 |
Why?
|
| Young Adult | 5 | 2020 | 21445 | 0.100 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 1323 | 0.100 |
Why?
|
| Family Practice | 1 | 2012 | 125 | 0.100 |
Why?
|
| Social Support | 2 | 2017 | 560 | 0.100 |
Why?
|
| Focus Groups | 1 | 2012 | 256 | 0.100 |
Why?
|
| Eating | 1 | 2013 | 421 | 0.100 |
Why?
|
| Internal Medicine | 1 | 2012 | 124 | 0.100 |
Why?
|
| Exercise | 3 | 2021 | 1183 | 0.090 |
Why?
|
| United States | 5 | 2019 | 15433 | 0.090 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 4298 | 0.090 |
Why?
|
| Gynecology | 1 | 2012 | 217 | 0.090 |
Why?
|
| Self Report | 1 | 2013 | 756 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2016 | 2316 | 0.090 |
Why?
|
| Pain | 2 | 2008 | 1658 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 3719 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 6207 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2017 | 10035 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 4988 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 227 | 0.080 |
Why?
|
| Fruit | 1 | 2010 | 294 | 0.080 |
Why?
|
| Affective Symptoms | 1 | 2008 | 102 | 0.080 |
Why?
|
| Fear | 1 | 2009 | 254 | 0.080 |
Why?
|
| Nigeria | 1 | 2007 | 74 | 0.080 |
Why?
|
| Prevalence | 3 | 2020 | 3260 | 0.080 |
Why?
|
| Vegetables | 1 | 2010 | 325 | 0.080 |
Why?
|
| Recurrence | 1 | 2016 | 4758 | 0.080 |
Why?
|
| Male | 9 | 2020 | 123000 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 980 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2010 | 551 | 0.070 |
Why?
|
| Cholesterol | 1 | 2010 | 658 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2013 | 1824 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 8865 | 0.070 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 2864 | 0.070 |
Why?
|
| Developing Countries | 1 | 2007 | 315 | 0.060 |
Why?
|
| Ethnology | 1 | 2004 | 3 | 0.060 |
Why?
|
| Prognosis | 4 | 2019 | 21713 | 0.060 |
Why?
|
| Motor Activity | 1 | 2008 | 693 | 0.060 |
Why?
|
| Marital Status | 1 | 2004 | 98 | 0.060 |
Why?
|
| Blood Glucose | 1 | 2009 | 1244 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2013 | 9180 | 0.060 |
Why?
|
| Education | 1 | 2004 | 112 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2007 | 2803 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2016 | 6869 | 0.060 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2004 | 70 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2013 | 14889 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2007 | 785 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2006 | 465 | 0.060 |
Why?
|
| ROC Curve | 2 | 2020 | 1183 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2022 | 2292 | 0.060 |
Why?
|
| Logistic Models | 1 | 2010 | 3441 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 4975 | 0.050 |
Why?
|
| Diet | 1 | 2010 | 1440 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2004 | 310 | 0.050 |
Why?
|
| Technology | 1 | 2022 | 96 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 748 | 0.050 |
Why?
|
| Patients | 1 | 2003 | 245 | 0.050 |
Why?
|
| Medically Underserved Area | 1 | 2021 | 101 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2016 | 12873 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2013 | 9244 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2010 | 6100 | 0.050 |
Why?
|
| Age Factors | 1 | 2009 | 5377 | 0.040 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2020 | 231 | 0.040 |
Why?
|
| Palladium | 1 | 2018 | 56 | 0.040 |
Why?
|
| Disease Progression | 1 | 2009 | 6682 | 0.040 |
Why?
|
| Palliative Care | 1 | 2009 | 2037 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 4971 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2016 | 32848 | 0.040 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2016 | 13 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 1000 | 0.030 |
Why?
|
| Machine Learning | 1 | 2018 | 319 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2016 | 666 | 0.030 |
Why?
|
| Health Status | 2 | 2008 | 590 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 6009 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2013 | 37905 | 0.030 |
Why?
|
| Algorithms | 2 | 2018 | 3890 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 2218 | 0.030 |
Why?
|
| Psychometrics | 1 | 2017 | 937 | 0.030 |
Why?
|
| Microscopy, Interference | 1 | 2011 | 16 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 10001 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 14289 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2016 | 2450 | 0.020 |
Why?
|
| Internet | 1 | 2013 | 706 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2016 | 4307 | 0.020 |
Why?
|
| Equipment Design | 1 | 2011 | 1204 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 3821 | 0.020 |
Why?
|
| Exercise Test | 1 | 2006 | 312 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 1946 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2004 | 170 | 0.010 |
Why?
|
| Walking | 1 | 2006 | 277 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2006 | 597 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2006 | 552 | 0.010 |
Why?
|
| Lymphedema | 1 | 2006 | 239 | 0.010 |
Why?
|
| Body Composition | 1 | 2006 | 595 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2009 | 1529 | 0.010 |
Why?
|
| Educational Status | 1 | 2004 | 397 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2008 | 992 | 0.010 |
Why?
|
| Self Concept | 1 | 2004 | 211 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 698 | 0.010 |
Why?
|
| Fatigue | 1 | 2008 | 1239 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 866 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 14551 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 8873 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2004 | 1225 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 2307 | 0.010 |
Why?
|
| Adolescent | 1 | 2020 | 31252 | 0.010 |
Why?
|
| Decision Making | 1 | 2007 | 1287 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2006 | 2203 | 0.010 |
Why?
|
| Biopsy | 1 | 2003 | 3443 | 0.010 |
Why?
|
| Texas | 1 | 2006 | 6311 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 4892 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 59536 | 0.010 |
Why?
|